Lexicon Pharma (LXRX) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.42 -4.05%
EPS Growth %: -50.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -50.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $18.3 million versus the consensus estimate of $17.71 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
